Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R01GM063075)
National Center for Complementary and Integrative Health (R01AT005076)
- License Information
-
More Information
Article History
Received: 31 March 2021
Accepted: 14 May 2021
First Online: 22 May 2021
Declarations
:
: Not applicable.
: Not applicable.
: H.W., J.L., and K.J.T. are co-inventors of a patent application (“<i>Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies</i>”) and a provisional patent application <i>(“Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-19”</i>). All other authors declare that they have no competing interests.
